A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2
Authors
Keywords
-
Journal
Cell Reports
Volume 38, Issue 3, Pages 110256
Publisher
Elsevier BV
Online
2021-12-23
DOI
10.1016/j.celrep.2021.110256
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection
- (2021) Philip J.M. Brouwer et al. CELL
- Emergence of SARS-CoV-2 B.1.1.7 Lineage — United States, December 29, 2020–January 12, 2021
- (2021) Summer E. Galloway et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- A Single Immunization with Spike-Functionalized Ferritin Vaccines Elicits Neutralizing Antibody Responses against SARS-CoV-2 in Mice
- (2021) Abigail E. Powell et al. ACS Central Science
- No higher infectivity but immune escape of SARS-CoV-2 501Y.V2 variants
- (2021) Qianqian Li et al. CELL
- Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
- (2021) Wilfredo F. Garcia-Beltran et al. CELL
- Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine induced sera
- (2021) Daming Zhou et al. CELL
- The Variant Gambit: COVID’s Next Move
- (2021) Jessica A. Plante et al. Cell Host & Microbe
- Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies
- (2021) Allison J. Greaney et al. Cell Host & Microbe
- Differential efficiencies to neutralize the novel mutants B.1.1.7 and 501Y.V2 by collected sera from convalescent COVID-19 patients and RBD nanoparticle-vaccinated rhesus macaques
- (2021) Rong Li et al. Cellular & Molecular Immunology
- Emergence of a Novel SARS-CoV-2 Variant in Southern California
- (2021) Wenjuan Zhang et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7
- (2021) Pengfei Wang et al. NATURE
- A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2
- (2021) Qingrui Huang et al. Nature Communications
- SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
- (2021) Markus Hoffmann et al. CELL
- The challenge of emerging SARS-CoV-2 mutants to vaccine development
- (2021) Rong Li et al. Journal of Genetics and Genomics
- Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses
- (2021) Kevin O. Saunders et al. NATURE
- Adjuvanting a subunit COVID-19 vaccine to induce protective immunity
- (2021) Prabhu S. Arunachalam et al. NATURE
- ‘Unprecedented achievement’: who received the first billion COVID vaccinations?
- (2021) Freda Kreier NATURE
- Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants
- (2021) Laith J. Abu-Raddad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351
- (2021) Xiaoying Shen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351)
- (2021) Thandeka Moyo-Gwete et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant
- (2021) Vivek Shinde et al. NEW ENGLAND JOURNAL OF MEDICINE
- Amino acids and RagD potentiate mTORC1 activation in CD8+ T cells to confer antitumor immunity
- (2021) Yiwen Zhang et al. Journal for ImmunoTherapy of Cancer
- Improvement of a SARS-CoV-2 vaccine by enhancing the conjugation efficiency of the immunogen to self-assembled nanoparticles
- (2021) Xiantao Zhang et al. Cellular & Molecular Immunology
- A novel coronavirus outbreak of global health concern
- (2020) Chen Wang et al. LANCET
- A pneumonia outbreak associated with a new coronavirus of probable bat origin
- (2020) Peng Zhou et al. NATURE
- Dual-targeting nanoparticle vaccine elicits a therapeutic antibody response against chronic hepatitis B
- (2020) Wenjun Wang et al. Nature Nanotechnology
- Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses
- (2020) Michael Letko et al. Nature Microbiology
- Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
- (2020) Alexandra C. Walls et al. CELL
- Recovered COVID-19 patients with recurrent viral RNA exhibit lower levels of anti-RBD antibodies
- (2020) Bingfeng Liu et al. Cellular & Molecular Immunology
- Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
- (2020) Cheryl Keech et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses
- (2020) Xiancai Ma et al. IMMUNITY
- A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge
- (2020) Yfat Yahalom-Ronen et al. Nature Communications
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started